Received Jun 30, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (UNKNOWN)) | UNKNOWN MANUFACTURER | UNK | — | — |
off-label use since the patient was instructed to receive a second dose of NUVAXOVID 3 to 8 weeks after the initial dose with no reported adverse event; Initial information received on 18-Jun-2026 regarding an unsolicited non-serious case received from a consumer (non-healthcare professional). This case involves an unknown age female patient who was instructed to receive a second dose of NVX-Cov2373 (Original) Adjuvanted Vaccine [Nuvaxovid] 3 to 8 weeks after the initial dose with no reported adverse event. The patient's past medical history, past drugs, vaccination(s), family history, concomitant medications were not provided. On an unknown date, the patient received dose 1 of NVX-Cov2373 (Original) Adjuvanted Vaccine as dispersion for injection of unknown strength (batch number and expiry date: unknown) via unknown route in unknown administration site for prophylactic vaccination [immunisaiton] On an unknown date, The patient was instructed to have her second dose of NVX-Cov2373 (Original) Adjuvanted Vaccine as dispersion for injection of unknown strength (batch number and expiry date: unknown) for for prophylactic vaccination [immunisaiton], 3 to 8 weeks after her initial dose with no reported adverse event (off label use) (latency: unknown). There will be no information on batch number and expiration date corresponding to the one at time of event occurrence. Patient called regarding a second dose of NUVAXOVID that she needs in order to continue her radiology program. As per the product insert, NUVAXOVID should be administered at least 2 months following any previous COVID-19 vaccination. The product was not used by or administered to the patient. Action taken: Not applicable